Blood Lipid Management Evaluation

If you're looking for a reliable partner to help you discover the relationship between your dietary supplements and blood lipid, look no further than the Creative Biogene Zebrafish Platform. Our team of experts is dedicated to providing high-quality services that help you discover the potential of your dietary supplements in blood lipid management. With our world-class facilities and cutting-edge technology, you can trust us to deliver reliable and accurate results every time. So why wait? Contact us now to learn more about how we can help you advance your goals.

Hyperlipidemia, characterized by elevated levels of blood lipids and associated lipoproteins, is a major contributor to cardiovascular diseases (CVDs), which rank as the top causes of mortality globally. Increased lipid circulation not only triggers atherosclerosis but also increases the risk of various human diseases.

As a vertebrate, zebrafish possesses major organs and tissues found in humans. Additionally, zebrafish has a similar genomic structure to humans. Moreover, zebrafish retains remarkable similarities with humans in molecular mechanisms associated with hyperlipidemia and atherosclerosis, including lipid metabolism and lipoprotein oxidation. These similarities allow the zebrafish model to serve as a surrogate to understand the underlying causes of hyperlipidemia and associated diseases in humans and to identify new therapeutic targets or dietary supplements for hyperlipidemia.

Fig. 1 Zebrafish hyperlipidemia model

Our Zebrafish-based Scientific Evaluation of Blood Lipid Management

At Creative Biogene Zebrafish Platform, we use egg yolk powder to establish a hyperlipidemia model in zebrafish and divide zebrafish into three groups: a vehicle group, a model group, and a dietary supplement group. After a period of administration of your products, we evaluate the potential of your dietary supplements in lowering blood lipid by oil red O staining and triglyceride content. Details are as follows.

Example Data

Fig. 2 Oil red O staining of zebrafish

Fig. 3 The effect of TCD treatment on total TG in HFD zebrafish

If you are interested in our services, please do not hesitate to contact us at any time or submit an inquiry to us directly. We are looking forward to cooperating with you.

References

1. Ka, J; Jin, S.W. Zebrafish as an emerging model for dyslipidemia and associated diseases. Journal of Lipid and Atherosclerosis. 2021, 10(1): 42.
2. Wu, S.; et al. Momordica charantia leaf extract reduces hepatic lipid accumulation and diet-induced dyslipidemia in zebrafish through lipogenesis and beta-oxidation. Journal of Functional Foods. 2021, 87: 104857.

For research use only. Not intended for any clinical use.